Alkermes Stock News

Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.

Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.

IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda

IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda

BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.

Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.

Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.

TCI Wealth Advisors Inc. boosted its stake in shares of Alkermes plc (NASDAQ:ALKS) by 527.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,541 shares of the companys stock after purchasing an additional 2,136 shares during the quarter. TCI []

Assenagon Asset Management S.A. bought a new stake in Alkermes plc (NASDAQ:ALKS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,381 shares of the companys stock, valued at approximately $320,000. A number of other hedge funds also recently made changes to their []

Cornerstone Investment Partners LLC lowered its holdings in Alkermes plc (NASDAQ:ALKS) by 19.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,525 shares of the companys stock after selling 1,800 shares during the quarter. Cornerstone Investment Partners LLCs holdings in Alkermes were worth $232,000 at the end of the most recent reporting period. Several []

Related Stocks: MRK , AZN , IDXX , GILD , CRL , PHG , MRNA , GH , QGEN , ALKS , BHVN , STVN , MTD , VRTX , QURE , ALXN , A , STE ,

Related Stocks: AMGN , NVAX , ITCI , SRPT , BGNE , GH , ALKS , AZN , CRBU , CRL , RLYB , BHVN , ALLK , BPMC , BBIO , IOVA , DCPH , REPL ,

Shares of Alkermes plc (NASDAQ:ALKS) have earned a consensus recommendation of Hold from the nine analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating on the company. The average 1 []

Royal Bank of Canada raised its stake in shares of Alkermes plc (NASDAQ:ALKS) by 119.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,920 shares of the companys stock after purchasing an additional 10,859 shares during the quarter. Royal Bank of Canadas []